4.13
price down icon0.24%   -0.010
after-market Dopo l'orario di chiusura: 4.14 0.010 +0.24%
loading
Precedente Chiudi:
$4.14
Aprire:
$4.07
Volume 24 ore:
449.12K
Relative Volume:
0.52
Capitalizzazione di mercato:
$396.50M
Reddito:
-
Utile/perdita netta:
$-238.77M
Rapporto P/E:
-0.1541
EPS:
-26.808
Flusso di cassa netto:
$-216.62M
1 W Prestazione:
+6.44%
1M Prestazione:
+36.75%
6M Prestazione:
-44.79%
1 anno Prestazione:
-67.45%
Intervallo 1D:
Value
$4.00
$4.28
Intervallo di 1 settimana:
Value
$3.75
$4.28
Portata 52W:
Value
$2.7601
$13.11

Alumis Inc Stock (ALMS) Company Profile

Name
Nome
Alumis Inc
Name
Telefono
650-231-6625
Name
Indirizzo
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
184
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
ALMS's Discussions on Twitter

Confronta ALMS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALMS
Alumis Inc
4.13 427.20M 0 -238.77M -216.62M -26.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Alumis Inc Stock (ALMS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-25 Iniziato Wells Fargo Overweight
2025-06-10 Ripresa Guggenheim Buy
2025-01-30 Iniziato Oppenheimer Outperform
2024-10-31 Iniziato Robert W. Baird Outperform
2024-10-17 Iniziato H.C. Wainwright Buy
2024-07-23 Iniziato Cantor Fitzgerald Overweight
2024-07-23 Iniziato Guggenheim Buy
2024-07-23 Iniziato Leerink Partners Outperform
2024-07-23 Iniziato Morgan Stanley Overweight
Mostra tutto

Alumis Inc Borsa (ALMS) Ultime notizie

pulisher
01:35 AM

How does Alumis Inc. compare to its industry peersDaily Trading Outlook With Proven Results - jammulinksnews.com

01:35 AM
pulisher
Jul 31, 2025

When is Alumis Inc. stock expected to show significant growthBreakout Stocks Updates With Proven Results - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

What institutional investors are buying Alumis Inc. stockTop Growth Planner For Every Investor - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - jammulinksnews.com

Jul 30, 2025
pulisher
Jul 30, 2025

What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Alumis (ALMS) Merges with ACELYRIN - Insider Monkey

Jul 29, 2025
pulisher
Jul 28, 2025

What is the risk reward ratio of investing in Alumis Inc. stockHarness the power of proven investment plans - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Alumis Inc. company’s balance sheetTop Growth Entry Points With Low Risk - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Alumis Inc. generate profit in a changing economyInvest confidently with professional advice - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Alumis Inc. stockUnlock your trading potential today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are analysts’ price targets for Alumis Inc. in the next 12 monthsHigh-performance investment picks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 26, 2025

Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Alumis initiated with an Overweight at Wells Fargo - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Alumis Inc. stock priceUnbelievable profit margins - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis completes enrollment in lupus treatment phase 2b trial By Investing.com - Investing.com India

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis completes enrollment in lupus treatment phase 2b trial - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

Alumis Inc. Completes Patient Enrollment in LUMUS Phase 2b Trial of ESK-001 for Systemic Lupus Erythematosus, Topline Data Expected Q3 2026 - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

Major Breakthrough: 408 Patients Enrolled in Advanced Trial for New Oral Lupus Treatment - Stock Titan

Jul 24, 2025

Alumis Inc Azioni (ALMS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Alumis Inc Azioni (ALMS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Tananbaum James B.
Director
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
Foresite Labs, LLC
10% Owner
May 02 '25
Buy
4.62
25,000
115,500
4,227,670
Foresite Labs, LLC
10% Owner
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
Foresite Capital Management VI
10% Owner
May 02 '25
Buy
4.62
25,000
115,500
4,227,670
Foresite Capital Management VI
10% Owner
May 06 '25
Buy
4.34
20,000
86,800
4,247,670
AKKARAJU SRINIVAS
Director
May 05 '25
Buy
4.67
160,370
749,676
3,586,788
AKKARAJU SRINIVAS
Director
May 02 '25
Buy
4.55
159,920
727,636
3,426,418
Colowick Alan
Director
Apr 01 '25
Buy
6.97
16,104
112,309
16,104
Colowick Alan
Director
Apr 02 '25
Buy
7.49
2,300
17,235
18,404
Babler Martin
President, CEO and Chairman
Apr 01 '25
Buy
6.44
15,650
100,733
106,454
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Capitalizzazione:     |  Volume (24 ore):